Bemcentinib

N/A

Report date: 2026/05/25 20:02:40
NMEFirst In Class

Base Information

Drug NameBemcentinib
Drug Alias NameBGB-324R-428BGB-3234
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsVirus internalization inhibitors
TargetsAXL receptor tyrosine kinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CNS Embryonal TumorMyelodysplastic Syndromes +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNetherlands +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterUT Health San AntonioGwt-Tud Gmbh +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsCNS Embryonal TumorTriple Negative Breast NeoplasmsInflammatory Breast Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG